Business Context and Reporting Period
This Form 8-K was filed by CalciMedica, Inc. on August 9, 2023. The report covers two primary events: the announcement of financial results for the fiscal quarter ended June 30, 2023 (issued via press release on August 10, 2023), and the results of the 2023 Annual Meeting of Stockholders held on August 9, 2023.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the financial results for the quarter ended June 30, 2023. However, the text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these details.
Material Changes and Corporate Actions
The filing details the outcomes of the 2023 Annual Meeting of Stockholders. As of the record date (June 23, 2023), 5,661,933 shares of common stock were outstanding and entitled to vote.
- Proposal 1 (Election of Class III Directors): Stockholders elected Robert N. Wilson and Allan Shaw to serve three-year terms through the 2026 annual meeting. Both candidates received overwhelming support with over 3.9 million votes "For" each.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023. The proposal passed with 4,208,835 votes "For" and only 2,269 votes "Against."
Guidance, Outlook, and Risks
The filing text does not contain specific management commentary, forward-looking guidance, risk factors, or contingencies regarding the company's future operations. It explicitly states that the information in Item 2.02 and the accompanying press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 10, 2023) for specific Q2 2023 financial figures (revenue, net loss, cash position) which are not included in this summary text.
- Confirm the terms of the newly elected directors (Robert N. Wilson and Allan Shaw) and their alignment with the company's strategic direction.
- Verify the continued engagement of Ernst & Young LLP as the independent auditor for the 2023 fiscal year.
- Note that the financial data in this report is not incorporated by reference into other SEC filings.